NAVIDEA BIOPHARMACEUTICALS I (NAVB)
US63937X2027 - Common Stock
| 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 2.00M | 4.23M | 2.67M | 1.05M | 3.48M | |||
| Marketable Securities | N/A | N/A | N/A | N/A | 799.27K | |||
| Receivables | 630.00 | 92.99K | 2.99M | 901.34K | 21.15K | |||
| Inventories | 427.34K | 151.16K | 169.80K | N/A | N/A | |||
| Other Current Assets | 780.11K | 908.27K | 700.72K | 967.29K | 1.30M | |||
| Total Current Assets | 3.20M | 5.38M | 6.53M | 2.92M | 5.60M | |||
| Non-Current Assets | ||||||||
| PPE Net | 155.65K | 248.71K | 382.26K | 311.90K | 162.17K | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Intangibles | 1.00M | 785.65K | 620.24K | 385.41K | 428.49K | |||
| Other Non-Current Assets | 11.77K | 227.19K | 227.19K | 537.81K | 835.11K | |||
| Total Non-Current Assets | 1.17M | 1.26M | 1.23M | 1.24M | 1.43M | |||
| TOTAL ASSETS | 4.37M | 6.64M | 7.76M | 4.15M | 7.02M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 543.61K | 453.43K | 745.44K | 305.96K | 316.07K | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | 320.00K | |||
| Accrued Expenses | 6.47M | 3.38M | 2.78M | 2.39M | 2.52M | |||
| Accounts Payable | 2.12M | 1.42M | 1.16M | 1.11M | 424.72K | |||
| Other Current Liabilities | 801.62K | 40.87K | 31.63K | 13.62K | 120.68K | |||
| Total Current Liabilities | 9.94M | 5.30M | 4.72M | 3.82M | 3.38M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 1.87M | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 701.31K | 720.29K | 996.01K | 1.21M | 1.23M | |||
| Total Non-Current Liabilities | 2.87M | 1.45M | 1.73M | 1.94M | 1.90M | |||
| TOTAL LIABILITIES | 12.81M | 6.75M | 6.44M | 5.76M | 5.28M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -388.00M | -370.79M | -359.06M | -347.67M | -336.72M | |||
| Additional Paid In Capital | 379.34M | 370.46M | 365.13M | 345.85M | 338.27M | |||
| Minority Interest | 292.52K | 731.30K | 731.30K | 731.32K | 668.70K | |||
| Common Shares | 223.69K | 221.35K | 219.27K | 211.13K | 200.39K | |||
| Other Shareholders' Equity | -8.44M | 0.00 | -4.97M | 0.00 | -730.00 | |||
| Shares Outstanding | 32.69M | 30.28M | 27.15M | 20.14M | 10.02M | |||
| Tangible Book Value per Share | -0.29 | -0.03 | 0.03 | -0.10 | 0.13 | |||
| Total Shareholders' Equity | -8.44M | -106.56K | 1.32M | -1.61M | 1.74M | |||
| TOTAL LIABILITIES AND EQUITY | 4.37M | 6.64M | 7.76M | 4.15M | 7.02M | |||
| Statistics | ||||||||
| Debt/Equity | -0.29 | N/A | N/A | N/A | N/A | |||
| Current Ratio | 0.32 | 1.02 | 1.38 | 0.76 | 1.66 | |||
| Return On Assets (ROA) | -393.79% | -176.54% | -146.76% | -263.75% | -229.49% | |||
| Return On Equity (ROE) | N/A | N/A | -865.43% | N/A | -924.95% | |||
All data in USD